Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: The University of Texas M. D. Anderson Cancer Center experience

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 5, 2008, Pages 1096-1103

  Dong, Wenli ^a   Berry, Donald A ^a   Bevers, Therese B ^a   Kau, Shu Wan ^a   Hsu, Limin ^a   Theriault, Richard L ^a   Shen, Yu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; UNITED STATES; BREAST TUMOR; CHI SQUARE DISTRIBUTION; DISEASE COURSE; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; STATISTICAL MODEL; TUMOR RECURRENCE;

ADULT; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TEXAS; TUMOR MARKERS, BIOLOGICAL;

EID: 52649177218     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0201     Document Type: Article

References (23)

1. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006;36:30-6.
2. Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361:1405-10.
3. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003;361:1411-7.
4. Humphrey LL, Helfand M, Chan BK, et al. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-60.
5. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
6. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.
7. Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005;97:1195-203.
8. Joensuu H, Lehtimaki T, Holli K, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004;292:1064-73.
9. Chu KC, Smart CR, Tarone RE. Analys is of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 1988;80:1125-32.
10. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 1992;147:1477-88.
11. McPherson CP, Swenson KK, Jolitz G, et al. Survival of women ages 40-49 years with breast carcinoma according to method of detection. Cancer 1997;79:1923-32.
12. Shapiro S, Goldberg JD, Hutchison GB. Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol 1974;100:357-66.
13. Connor RJ, Chu KC, Smart CR. Stage-shift cancer screening model. J Clin Epidemiol 1989;42:1083-95.
14. Schootman M, Fuortes L, Aft R. Prognosis of metachronous contralateral breast cancer according to stage at diagnosis: the importance of early detection. Breast Cancer Res Treat 2006;99:91-5.
15. Morrison AS. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol 1982;11:261-7.
16. Baum M. Breast cancer screening comes full circle. J Natl Cancer Inst 2004;96:1490-1.
17. Krzyzanowska MK, Tannock IF. Should screen-detected breast cancers be managed differently? J Natl Cancer Inst 2005;97:1170-1.
18. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999;91:2020-8.
19. Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000;92:743-9.
20. Narod SA, Dube MP. Re: Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2001;93:151-2.
21. Shen Y, Dong W, Esteva FJ, et al. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat 2007;102:347-56.
22. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003;97:134-47.
23. Smith-Bindman R, Miglioretti DL, Lurie N, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med 2006;144:541-53.